FDA Advisory Committees to Consider Link Between Lou Gehrig’s Disease and Statins
Although much of the attention during the joint Nonprescription Drugs and Endocrinologic and Metabolic Drugs advisory committee meeting scheduled for Dec. 13 will pertain to Merck’s OTC-switch application for its statin Mevacor (see story), the committee likely will be asked to weigh in on a potential link between the use of statins and Lou Gehrig’s disease.

http://fdanews.com/newsletter/articl...ticleId=102110